Clinical Study

Predictive Role of ADA in Bronchoalveolar Lavage Fluid in Making the Diagnosis of Pulmonary Tuberculosis

Fariba Binesh1 and Abolhassan Halvani2

1 Department of Pathology, Shahid Sadoughi University of Medical Sciences, Yazd 8919337692, Iran
2 Mortaz Hospital, Kashani Street, Yazd 8915173143, Iran

Correspondence should be addressed to Abolhassan Halvani; halvani47@yahoo.com

Received 16 August 2013; Accepted 1 October 2013

Academic Editor: Leif Bjermer

Copyright © 2013 F. Binesh and A. Halvani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Current diagnostic tests for tuberculosis (TB) are time-consuming. The aim of this study was to evaluate the diagnostic usefulness of ADA in bronchoalveolar lavage fluid in patients with pulmonary TB. A cross-sectional study was performed in Yazd, Iran, between 2009 and 2010. Patients suspected of pulmonary TB with negative sputum smear for AFB were included in the study. Mean ADA levels in BAL fluids were measured and compared between study groups. Sixty-three patients were enrolled in the study among which 15 cases had pulmonary TB, 33 had pulmonary diseases other than TB, and 15 subjects with normal bronchoscopy results were considered as controls. Mean ADA level in BAL fluid were 4.13 ± 2.55, 2.42 ± 1.06, and 1.93 ± 0.88, respectively. This rate was significantly higher in the pulmonary TB group compared to the other two groups (P = 0.001). Using ROC curve with a cut-off value of 3.5 IU/L, the highest sensitivity (57%) and specificity (84%) were obtained in diagnosis of TB. The results showed that although ADA activity in BAL fluid of pulmonary TB patients was higher than those seen in other diseases, a negative test does not rule out pulmonary TB.

1. Introduction

Tuberculosis (TB) is the second most important cause of death from infectious diseases in the world [1]. It is a major public health problem in developing countries including Iran. Multidrug resistance in tuberculosis and its association with acquired immunodeficiency syndrome (AIDS) have further highlighted the importance of this disease. The diagnosis is usually based on clinical presentation, radiologic findings, and positive tuberculin and/or skin tests. However, clinicoradiological features are variable and the latter tests may be falsely negative. The gold standard of TB diagnosis requires the growth of Mycobacterium in specimen cultures, but the cultures are time-consuming and have low positivity rates, with a mean sensitivity of 43%–83% depending on the quality of samples cultured and methods utilized [2]. Since delay is unacceptable in emergency situations, it is necessary to find faster methods with higher sensitivity. The polymerase chain reaction (PCR) assay has shown good sensitivity and specificity in some studies [3], but it is not cost-effective and few centers use it in Iran. Several biomarkers like adenosine deaminase (ADA), interferon gamma (IFN-γ), and a variety of tumor markers and cytokines have been proposed as alternative noninvasive means of establishing tuberculous etiology [4]. ADA is an enzyme involved in purine catabolism, catalyzing the pathway from adenosine to inosine and is known as a cellular immunity marker. ADA activity has been assessed in various fluids of TB patients for diagnosis of pleural, cerebrospinal, peritoneal, and synovial TB [3, 5–7]. To our knowledge, a few studies [8–11] have evaluated BALF ADA activity for the diagnosis of TB and the results are variable. Therefore, the aim of this study was to calculate the cut-off point for ADA activity in the BALF of patients with TB in a local Iranian population.

2. Materials and Methods

A cross-sectional descriptive study was performed at the Shahid Sadoughi Hospital in Yazd, Iran, between 2009 and 2010. This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical
Samples were centrifuged and kept at −21°C for AFB smear and culture. To assess ADA activity, the fluid was collected via aspiration and sent to the laboratory for BAL fluid. 150 cc normal saline was injected and the returned fluid was collected via a suction and sent to the laboratory for AFB smear and culture. To assess ADA activity, the samples were centrifuged and kept at −21°C. Then ADA levels in BAL fluids were compared to each other by ADA kit (Shim Enzyme CO.). ADA activity was measured by Giusti’s colorimetric method. In Giusti’s the first step is deamination of adenosine and releasing ammonia. The second reaction is catalyzed by glutamate dehydrogenase accompanying an allosteric activator. Low light absorption at 340 nm has a direct relationship to ADA activity. By this method, ADA activity can be measured up to 100 IU/L. Those patients who had positive sputum cultures or BAL cultures for AFB were selected as the pulmonary TB group; those who had other forms of pulmonary diseases and were negative for TB were included in the non-TB lung disease group. Individuals, in which TB and other pulmonary diseases were ruled out, were selected as the control group. Questionnaires were filled for all three groups and mean ADA levels in BAL fluids were measured and compared. Data were analyzed by independent t-test, ANOVA, and Fisher’s exact test using SPSS software ver. 11.5.

### 3. Results

Sixty-three patients were enrolled in this study. Fifteen patients (5 males, 10 females; mean age: 64.06 ± 19.37 years) had pulmonary TB, 33 (22 males, 11 females; mean age: 56.18 ± 18.60 years) had non-TB lung disease, and 15 cases (10 males, 5 females; mean age: 42.13 ± 21.45 years) were controls. Among non-TB lung disease patients, 5 patients had interstitial lung disease (1 Wegener’s disease, 2 cases of usual interstitial pneumonia, 1 case of sarcoidosis, and 1 silicosis), 14 had lung cancer (6 adenocarcinomas, 4 squamous cell carcinomas, 1 small cell carcinoma, 2 non-Hodgkin’s lymphomas, and 1 primary pulmonary Hodgkin’s lymphoma), 4 had pneumonia, and 10 patients had chronic obstructive pulmonary disease (COPD). Control subjects undergoing bronchoscopy for various reasons and no pathologic findings could be reached eventually. Sputum culture, BAL smear, and BAL culture were positive in 5, 8, and 11 patients, respectively, in pulmonary TB group. As a whole, all TB patients had positive sputum culture or positive-BAL culture (Table 1).

|                  | Smear Culture |   |   |   |
|------------------|---------------|---|---|---|
|                  | Negative      | Positive | Negative | Positive |
| Sputum N (%)     | 15 (100%)     | 0 (0%)   | 10 (67%) | 5 (33%)   |
| BAL fluid N (%)  | 7 (47%)       | 8 (53%)  | 4 (27%)  | 11 (73%)  |

### Table 2: Mean and SD of ADA level in BAL of patients in 3 study groups.

|                  | Mean ± SD | Maximum | Minimum |
|------------------|-----------|---------|---------|
| Pulmonary TB      | 4.13 ± 2.55 | 10      | 1       |
| Non-TB lung disease | 2.42 ± 1.06 | 5       | 1       |
| Control           | 1.93 ± 0.88 | 4       | 1       |

Based on the results, ADA level was 2.43 ± 1.23 IU/L in women and 3.11 ± 2.17 IU/L in men; independent t-test did not show a significant difference between the two groups (P = 0.11, t = 1.58). To determine the best predictive value of ADA levels in diagnosis of pulmonary TB, a ROC curve was used which did not show a significant difference (P = 0.10). At the designated cut-off level of 3.5 IU/L, the highest sensitivity and...
specificity for diagnosis of TB were found (specificity = 84%, sensitivity = 57%). Using cut-off point in ADA = 2.2 IU/L (mean ADA + 2 × SD) in the control group, the sensitivity, specificity, positive-predictive, and negative-predictive values were 73%, 67%, 41%, and 89%, respectively.

4. Discussion

Our findings showed a significant difference in ADA levels among three groups and ADA level was significantly higher in TB patients than in the other two groups. ADA is an enzyme that increases in TB because of the stimulation of T-cell lymphocytes by mycobacterial antigens. Since 1978, when ADA activity was found to be high in tuberculous exudates [12], ADA has been used in the diagnosis of tuberculosis [13, 14]. The laboratory method for measuring ADA is inexpensive and relatively simple to perform. Thus, it may be useful in laboratories with limited resources, particularly in developing countries such as Iran. Orphanidou et al. [11] compared ADA activity and lysozyme levels in BAL fluid of smear-negative pulmonary TB patients and non-TB lung disease patients and found that there was no significant difference in lysozyme levels of BAL fluids between the two groups, but ADA level in BAL fluids of pulmonary TB patients was significantly higher than that of non-TB lung disease patients (P < 0.001). In a study conducted by Kubota et al. [10] mean ADA level in BAL fluid of miliary TB patients, sarcoidosis patients, idiopathic interstitial pneumonia patients, and control group was 5.02 ± 3.75 IU/L, 1.06 ± 0.99 IU/L, 0.21 ± 0.43 IU/L, and 0.3 ± 0.51 IU/L, respectively, and ADA level in BAL fluid of miliary TB patients was higher than that of other groups (P < 0.01). In a study by Kayacan et al. [8], ADA level in BAL fluids of pulmonary TB patients, non-TB lung disease patients (like interstitial lung disease, lung cancer, pneumonia, and COPD) and controls was 3.1 ± 2.1 IU/L, 0.4 ± 0.5 IU/L, and 0.2 ± 0.4 IU/L, respectively, (P < 0.001). However, Reechoipichitkul et al. [9] compared ADA levels in BAL fluid of pulmonary TB patients, lung cancer patients, and those with other forms of pulmonary diseases and found no significant difference among these three groups (P = 0.56).

Orphanidou et al. [15] showed that ADA level in BAL fluid of patients with pulmonary TB is significantly higher than that of other pulmonary diseases. On the other hand, Boonsarngsuk et al. [16] revealed that BALF ADA had limited value in differentiating pulmonary TB from some other pulmonary diseases. To explain these discrepancies, differences between reported ADA levels and their sensitivity and specificity in different studies, it must be considered that it may be due to different methods of ADA measurement, presence of other diseases, and differences in the technique of bronchoalveolar lavage. In addition, BAL fluid ADA activity may differ from one human race to another [17]. It seems, therefore, that the cut-off value should be ideally based on the results of local studies or studies performed in similar populations and with the same methodology. TB epidemiology is also important. It should be noted that the value of any diagnostic test has been related to its disease prediction ability. Positive predictive value (PPV) in diagnostic studies is related to disease prevalence and thus in population with lower prevalence we suspected to have low PPV. On the other hand it should be remembered that the predictive value of ADA depends not only on its sensitivity and specificity but also on the local prevalence of the disease. When the prevalence rose, the PPV increased [18]. The opposite relation refers to negative predictive value (NPV). Furthermore, most studies are on the total ADA level, but ADA isoenzymes may be more accurate. We were unable to determine ADA isoenzymes. However, in this study at the designated cut-off level = 3.5 IU/L, a specificity = 84% was obtained which indicated that ADA > 3.5 IU/L can confidently rule out non-TB pulmonary diseases.

In conclusion, although ADA level in BAL fluid of patients with pulmonary TB is significantly higher than that of other pulmonary diseases and is a rapid and cost-effective method, its sensitivity is not able to rule out pulmonary TB. Therefore, studies with a larger sample size are recommended.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgment

This work was supported by Shahid Sadoughi University of medical sciences and health services, Yazd, Iran.

References

[1] G. Caramori, L. Lasagna, A. G. Casalini et al., “Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy,” PLoS ONE, vol. 6, no. 7, Article ID e22637, 2011.
[2] L. J. Burgess, C. G. Swanepoel, and J. F. Taljaard, “The use of adenosine deaminase as a diagnostic tool for peritoneal tuberculosis,” Tuberculosis, vol. 81, no. 3, pp. 243–248, 2001.
[3] V. Hallur, M. Sharma, S. Sethi et al., “Development and evaluation of multiplex PCR in rapid diagnosis of abdominal tuberculosis,” Diagnostic Microbiology and Infectious Disease, vol. 76, no. 1, pp. 51–55, 2013.
[4] Z. D. Daniil, E. Zintzaras, T. Kiropoulos et al., “Discrimination of exudative pleural effusions based on multiple biological parameters,” European Respiratory Journal, vol. 30, no. 5, pp. 957–964, 2007.
[5] J. Klimus and R. Krenke, “Role of biomarkers in making the diagnosis of tuberculous pleurisy,” Pneumonologia i Alergologia Polska, vol. 79, no. 4, pp. 288–297, 2011.
[6] A. Moghtaderi, A. Nazi, R. Alavi-Naini, S. Yaghhoobi, and B. Narouie, “Comparative analysis of cerebrospinal fluid adenosine deaminase in tuberculous and non-tuberculous meningitis,” Clinical Neurology and Neurosurgery, vol. 112, no. 6, pp. 459–462, 2010.
[7] C. Foocharoen, C. Sarntippipattana, T. Foocharoen et al., “Synovial fluid adenosine deaminase activity to diagnose tuberculous septic arthritis,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 42, no. 2, pp. 331–337, 2011.
[8] O. Kayacan, D. Karnak, M. Delibalta, S. Beder, L. Karaca, and H. Tutkak, “Adenosine deaminase activity in bronchoalveolar
lavage in Turkish patients with smear negative pulmonary tuberculosis," *Respiratory Medicine*, vol. 96, no. 7, pp. 536–541, 2002.

[9] W. Reechaipichitkul, V. Lulitanond, B. Patjanaasontorn, W. Boonsawat, and A. Phunmanee, “Diagnostic yield of adenosine deaminase in bronchoalveolar lavage,” *Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 35, no. 3, pp. 730–734, 2004.

[10] M. Kubota, M. Katagiri, N. Yanase, K. Soma, and T. Tomita, “Measurement of adenosine deaminase activity in bronchoalveolar lavage fluids as a tool for diagnosing miliary tuberculosis,” *Nihon Kyobu Shikkan Gakkai Zasshi*, vol. 34, no. 2, pp. 139–144, 1996.

[11] D. Orphanidou, M. Gaga, A. Rasidakis et al., “Tumour necrosis factor, interleukin-1 and adenosine deaminase in tuberculous pleural effusion,” *Respiratory Medicine*, vol. 90, no. 2, pp. 95–98, 1996.

[12] M. A. Piras, C. Gakis, M. Budroni, and G. Andreoni, “Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis,” *British Medical Journal*, vol. 2, no. 6154, pp. 1751–1752, 1978.

[13] L. Valdes, E. San Jose, D. Alvarez et al., “Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma,” *Chest*, vol. 103, no. 2, pp. 458–465, 1993.

[14] J. F. Bueso, H. V. Hernando, J. P. Garcia-Buela, L. D. Juncal, M. T. M. Egana, and M. C. M. Martinez, “Diagnostic value of simultaneous determination of pleural adenosine deaminase and pleural lysozyme/serum lysozyme ratio in pleural effusions,” *Chest*, vol. 93, no. 2, pp. 303–307, 1988.

[15] D. Orphanidou, G. Stratakos, A. Rasidakis et al., “Adenosine deaminase activity and lysozyme levels in bronchoalveolar lavage fluid in patients with pulmonary tuberculosis,” *International Journal of Tuberculosis and Lung Disease*, vol. 2, no. 2, pp. 147–152, 1998.

[16] V. Boonsarngsuk, S. Suwannaphong, and C. Laohavich, “Combination of adenosine deaminase activity and polymerase chain reaction in bronchoalveolar lavage fluid in the diagnosis of smear-negative active pulmonary tuberculosis,” *International Journal of Infectious Diseases*, vol. 16, no. 9, pp. e663–e668, 2012.

[17] S. H. Choi, Y. S. Kim, I. G. Bae et al., “The possible role of cerebrospinal fluid adenosine deaminase activity in the diagnosis of tuberculous meningitis in adults,” *Clinical Neurology and Neurosurgery*, vol. 104, no. 1, pp. 10–15, 2002.

[18] S. Greco, E. Girardi, R. Masciangelo, G. B. Capoccetta, and C. Saltini, “Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis,” *International Journal of Tuberculosis and Lung Disease*, vol. 7, no. 8, pp. 777–786, 2003.